InspireMD, Inc. (NSPR)
$0.84-$0.04 (-4.35%) Today
Shane Thomas Gleason - OfficerShane Thomas Gleason - OfficerShane Thomas Gleason - OfficerShane Thomas Gleason - OfficerShane Thomas Gleason - OfficerShane Thomas Gleason - OfficerShane Thomas Gleason - OfficerInspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
No Form 4 activity for NSPR in the last 90 days.
36 Form 4 filings on record, the earliest from Jun 25, 2025, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Paul Stuka - Director | Open-market purchase | Common Stock | 20,000 | $0.88 | $18K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 3,858 | $2.71 | $10K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 2,476 | $2.61 | $6K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 3,660 | $2.46 | $9K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 2,454 | $2.51 | $6K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 9,923 | $2.55 | $25K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 7,073 | $2.51 | $18K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 5,132 | $2.46 | $13K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 10,000 | $3.65 | $37K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 2,482 | $2.51 | $6K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 1,572 | $2.51 | $4K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 3,760 | $2.51 | $9K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 7,186 | $2.51 | $18K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 2,941 | $1.59 | $5K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 22,778 | $1.01 | $23K | |
| Paul Stuka - Director | Open-market purchase | Common Stock | 5,000 | $1.15 | $6K | |
| Paul Stuka - Director | Open-market purchase | Common Stock | 10,000 | $1.16 | $12K | |
 Marvin Slosman - Officer | Open-market purchase | Common Stock | 21,000 | $1.20 | $25K | |
| Paul Stuka - Director | Open-market purchase | Common Stock | 65,626 | $1.16 | $76K | |
| Paul Stuka - Director | Open-market purchase | Common Stock | 10,000 | $1.19 | $12K | |
| Paul Stuka - Director | Open-market purchase | Common Stock | 65,626 | $1.16 | $76K | |
| Paul Stuka - Director | Open-market purchase | Common Stock | 10,000 | $1.19 | $12K | |
| Scott R. Ward - Director | Open-market purchase | Common Stock | 73,255 | $1.15 | $84K | |
| Scott R. Ward - Director | Open-market purchase | Common Stock | 15,995 | $1.15 | $18K | |
| Paul Stuka - Director | Open-market purchase | Common Stock | 1,517 | $1.12 | $2K | |
| Paul Stuka - Director | Open-market purchase | Common Stock | 6,378 | $1.15 | $7K | |
 Gary S. Roubin - Director | Open-market purchase | Common Stock | 90,000 | $1.18 | $106K | |
| Paul Stuka - Director | Open-market purchase | Common Stock | 2,710 | $1.81 | $5K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 2,909 | $1.58 | $5K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 2,250 | $1.61 | $4K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 2,955 | $1.59 | $5K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 17,593 | $1.62 | $29K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 8,411 | $1.57 | $13K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 4,781 | $1.66 | $8K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 12,395 | $1.65 | $20K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 5,000 | $1.65 | $8K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 2,900 | $1.63 | $5K | |
| Shane Thomas Gleason - Officer | Open-market sale | Common Stock | 2,000 | $1.60 | $3K | |
| Scott R. Ward - Director | Grant or award | Common Stock | 88,053 | $0.00 | - | |
| Andrea Tommasoli - Officer | Grant or award | Common Stock | 226,695 | $0.00 | - | |
| Paul Stuka - Director | Grant or award | Common Stock | 132,076 | $0.00 | - | |
| Marvin Slosman - Officer | Grant or award | Restricted Stock Units | 1,114,792 | $0.00 | - | |
| Gary S. Roubin - Director | Grant or award | Common Stock | 88,053 | $0.00 | - | |
 Michael A. Lawless - Officer | Grant or award | Common Stock | 226,695 | $0.00 | - | |
| Shane Thomas Gleason - Officer | Grant or award | Common Stock | 453,390 | $0.00 | - | |
| Danny L. Dearen - Director | Grant or award | Common Stock | 44,030 | $0.00 | - | |
 Raymond W. Cohen - Director | Grant or award | Common Stock | 44,030 | $0.00 | - | |
 Michael Berman - Director | Grant or award | Common Stock | 88,053 | $0.00 | - | |
 Kathryn Arnold - Director | Grant or award | Common Stock | 55,556 | $0.00 | - | |
| Kathryn Arnold - Director | Grant or award | Options to purchase common stock (right to buy) | 26,276 | $0.00 | - | |
| Paul Stuka - Director | Open-market purchase | Common Stock | 5,073 | $1.81 | $9K | |
| Paul Stuka - Director | Open-market purchase | Common Stock | 5,073 | $1.86 | $9K | |
| Paul Stuka - Director | Open-market purchase | Common Stock | 10,130 | $1.85 | $19K | |
| Paul Stuka - Director | Open-market purchase | Common Stock | 13,431 | $1.62 | $22K | |
| Gary S. Roubin - Director | Grant or award | Common Stock | 48,000 | $0.00 | - | |
 Thomas J. Kester - Director | Grant or award | Common Stock | 37,815 | $0.00 | - | |
| Thomas J. Kester - Director | Grant or award | Options to purchase common stock (right to buy) | 19,041 | $0.00 | - | |
| Gary S. Roubin - Director | Open-market purchase | Common Stock | 41,322 | $2.42 | $100K | |
| Thomas J. Kester - Director | Open-market purchase | Common Stock | 30,991 | $2.42 | $75K |
InspireMD, Inc. (NSPR) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-05-29. The full record for NSPR runs to 36 Form 4 filings, the earliest from 2025-06-25. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of NSPR were filed in the last 90 days. 22 purchases are on record for this company.
No insider sales of NSPR were filed in the last 90 days. 24 sales are on record for this company.
This page tracks NSPR Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add NSPR to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
